Cartesian updates Descartes-08 pipeline; IND accepted in myositis, pediatric trial initiated

Cartesian Therapeutics, Inc.

Phase 3 AURORA trial for Descartes-08 in myasthenia gravis enrollment on track; data expected to support cash runway into mid-2027.
FDA accepted IND for Descartes-08 in myositis; seamless adaptive Phase 2 TRITON trial expected to start 1H26.
Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomyositis initiated.
Two Nature Medicine publications; Phase 2b MG data showed 55% median prednisone dose reduction at Month 12, no CRS or ICANS.
Cash resources expected to fund operations including Phase 3 trial completion through mid-2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.